For most of its life, Arcutis Biotherapeutics was a company with a single compelling bet: that a molecule called roflumilast, already proven in lung disease, could be reformulated as a cream and quietly transform how dermatologists treat stubborn skin conditions. For years, the bet cost money, reliably. Then, in 2024, prescriptions started filling. By 2025, the math looked almost unrecognizable.
Here is the contrast that should not coexist: a company that was losing several dollars per share as recently as 2022 posted a loss of just thirteen cents per share in FY2025, while revenue nearly doubled year over year. The losses are not gone, but they are collapsing faster than almost anyone in early-stage biotech manages. And the label on its lead product just got bigger again.
The gist of it
Arcutis filed FY2025 revenue of $376 million, up 91% from the year before, while its net loss shrank to roughly 4 cents on every dollar of sales. The stock has risen sharply over the past twelve months and sits near its 52-week high, meaning the market is already pricing in a lot of that improvement. The open question is whether a label that now reaches children as young as two, and may soon cover infants, can push the math from “almost profitable” to “actually profitable” before the mood gets ahead of itself.
One molecule, many labels
Zoryve cream started life approved for adults and older children with plaque psoriasis. On June 29, 2026, the FDA extended that approval to children as young as two, supported by a maximal-usage safety study and a 24-week open-label extension that showed the same tolerability profile seen in adults. Before this, the lower age limit was six. Moving it to two does not sound dramatic until you consider that pediatric skin conditions are chronically undertreated, partly because parents and physicians are reluctant to use steroid-based creams on young children for extended periods. Roflumilast is not a steroid, and the new label carries no duration limit, which matters enormously in a condition that flares and recurs for years.
The next step is potentially larger still. The FDA accepted a supplemental application for a lower-concentration version of the cream for atopic dermatitis in infants aged three to twenty-four months, with a PDUFA decision date of February 23, 2027. Atopic dermatitis in infants is one of the most common skin conditions a pediatrician sees, and safe topical options for that age group are scarce. A positive decision would open a patient population the current label cannot touch.
What the filing year actually shows
The FY2025 10-K shows revenue of $376 million against $197 million the year before, a near-doubling driven entirely by Zoryve prescriptions filling at scale. The net margin, meaning what is left after every cost, was negative 4.3% in 2025, compared with negative 71% in FY2024. Think of it this way: a year ago, for every dollar that came in the door, the company burned through roughly $1.71 in total. By the end of 2025, it was spending $1.04. The direction is clear; the finish line is close but not yet crossed.
Our data puts the current price-to-sales multiple, which is the price tag the market assigns per dollar of annual revenue, at 10.8 times, against a historical median of 9.3 times for Arcutis itself. That puts the stock above its own historical median valuation, meaning the market is paying a premium to what it has historically paid, on the assumption that the revenue growth continues. That assumption is not unreasonable given the label expansions, but it is an assumption, not a certainty.
The program that didn’t make it
Not every bet paid off. ARQ-252, a topical JAK1 inhibitor (a class of drug that dials down the immune signals driving inflammation), failed in clinical trials for both chronic hand eczema and vitiligo. The molecule was not the problem; the formulation was. It could not deliver enough drug through the skin to matter. Arcutis terminated the vitiligo trial and sent the compound back to preclinical work, where it remains as of early 2026. The company’s strategic answer to that setback was to concentrate resources on roflumilast, which has now proven it can reach the skin effectively across multiple formulations and concentrations. That focus is visible in the revenue line.
Reading the numbers
- $376 million in FY2025 revenue (from the FY2025 10-K): this is what Zoryve prescriptions generated in a full commercial year. It means the drug is filling at meaningful scale, not just sampling. A household analogy: if the business were a bakery, it sold nearly twice as many loaves in 2025 as in 2024, without opening a second location.
- Net margin of negative 4.3% in FY2025 vs. negative 71.3% in FY2024: the margin is what remains of each dollar of revenue after every cost is paid. Moving from negative 71% to negative 4% in a single year means the company is spending almost exactly what it takes in, rather than burning through multiples of it. A household that spent $1.71 for every dollar earned in 2024 spent $1.04 in 2025. The gap to breakeven is now measured in cents, not dollars.
- EPS of negative $0.13 in FY2025 vs. negative $5.66 in FY2022: earnings per share, the loss divided across all shares outstanding, shrank by roughly 98% over three years. This is the filed trend that the market is extrapolating forward. If it continues, the company reaches profitability. If revenue growth stalls, it does not.
- Price-to-sales of 10.8 times (our data, computed from market price and filed revenue): the market is paying $10.80 for every dollar of annual sales. The company’s own historical median is $9.30. That gap, about $1.50 per dollar of sales, is the “mood” premium, meaning what optimism is currently worth in price terms. If revenue growth lands near the filed trend, the historical multiple would put the price in a range consistent with today. If growth disappoints, that premium compresses.
Sources
- 10-Q for quarter ended June 30, 2026
- 10-K for fiscal year ended December 31, 2025
- 10-K for fiscal year ended December 31, 2024
- Arcutis Q2 2026 business update
- Dermatology Times: FDA approval for children age 2
- Arcutis ARQ-252 vitiligo trial update
